| Literature DB >> 36133736 |
Harjit Dumra1, Arjun Khanna2, Sujeet K Madhukar3, Meena Lopez4, Jaideep Gogtay4.
Abstract
Purpose: The aim of the survey was to evaluate attitudes and perceptions toward nebulization therapy for the management of chronic obstructive pulmonary disease (COPD) in Indian population. Patients and methods: A cross-sectional, multicenter, quantitative survey was conducted from July to August 2019 among 103 COPD patients [>40 years, either gender, belonging to socio-economic class (SEC) A or SEC B] and their family caregivers. One-on-one interviews were conducted telephonically via an online survey platform (KoBo data collection tool) using a structured questionnaire. Patients receiving home nebulization were included, and the usage of nebulizers, satisfaction, and benefits and concerns with nebulizers were assessed.Entities:
Keywords: home nebulization; nebulization; nebulizer device; patient attitude; patient perception; quality of life; quantitative survey; satisfaction
Mesh:
Substances:
Year: 2022 PMID: 36133736 PMCID: PMC9482889 DOI: 10.2147/COPD.S367819
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Demographics of Patients Included in the Survey
| Characteristics | Subcategory | Patients |
|---|---|---|
| Gender | Male | 53% |
| Female | 47% | |
| Age (years) | 40–50 | 36% |
| 51–60 | 23% | |
| 61–70 | 31% | |
| 71–80 | 10% | |
| SEC | SEC A | 54% |
| SEC B | 46% | |
| Education of CWE of the household | Graduate/postgraduate – general | 51% |
| SC/HSC | 21% | |
| Graduate/postgraduate – Professional | 14% | |
| College, but not graduate | 13% | |
| Occupation of the CWE | Shop owners | 27% |
| Officer/executives: middle/seniors | 17% | |
| Officer/executives: juniors | 14% | |
| Businessmen/industrialist (with 1 to 9 employees) | 13% |
Abbreviations: CWE, chief wage earner; SC, secondary certificate; HSC, higher secondary certificate; SEC, socio-economic class.
Overall and Subgroup Profile of the Patients and Family Caregivers
| Patient Profile | Trends | Overall (%) | SEC A (%) | SEC B(%) | Male (%) | Female (%) |
|---|---|---|---|---|---|---|
| More than 5 years | 46 | 38 | 55 | 40 | 52 | |
| 3–5 years | 25 | 26 | 24 | 35 | 14 | |
| Once daily | 29 | 23 | 37 | 39 | 18 | |
| Once a week | 30 | 31 | 29 | 21 | 40 | |
| Walking for 100 m or after few minutes | 50 | 43 | 57 | 51 | 48 | |
| Hurrying or walking 2 steps slight uphill | 26 | 34 | 16 | 21 | 32 | |
| Recommended by doctor | 41 | 38 | 45 | 32 | 52 | |
| Spouse | 23 | 19 | 29 | 33 | 12 | |
| Children | 15 | 21 | 8 | 11 | 20 | |
| Children | 40 | 43 | 37 | 33 | 48 | |
| Spouse | 36 | 30 | 43 | 49 | 20 | |
| Spouse | 33 | 27 | 40 | 20 | 44 | |
| Parents | 30 | 31 | 29 | 38 | 23 | |
| More than 6 months | 85 | 81 | 91 | 78 | 91 | |
| 3–6 months | 9 | 13 | 4 | 14 | 5 | |
| Walking for 100 m or after few minutes | 50 | 44 | 60 | 56 | 46 | |
| Rest or feeling too breathless to leave the house | 26 | 26 | 27 | 16 | 35 | |
| Between 5–10 hours per week | 37 | 45 | 27 | 28 | 37 | |
| Between 16–20 hours per week | 13 | 6 | 22 | 14 | 12 | |
| More than 20 hours per week | 24 | 24 | 24 | 20 | 28 | |
Abbreviation: COPD, chronic obstructive pulmonary disorder.
Overall and Subgroup Trends for Drugs Used in Nebulization Therapy
| Drugs | Overall (in %) | SEC A (in %) | SEC B (in %) | Male (in %) | Female (in %) |
|---|---|---|---|---|---|
| Formoterol + Budesonide | 46 | 52 | 39 | 45 | 46 |
| Budesonide | 31 | 33 | 24 | 26 | 34 |
| Levosalbutamol + Ipratropium | 29 | 33 | 24 | 34 | 26 |
| Levosalbutamol | 20 | 20 | 18 | 19 | 22 |
| Salbutamol | 19 | 19 | 18 | 19 | 18 |
| Levosalbutamol + Budesonide | 3 | 2 | 4 | 4 | 2 |
| Glycopyrrolate | 3 | 6 | 0 | 6 | 0 |
| Salmeterol + Fluticasone Propionate | 2 | 2 | 2 | 4 | 0 |
Overall and Subgroup Trends in Usage of Nebulization Therapy
| Parameter | Trend | Overall (%) | SEC A (%) | SEC B (%) | Male (%) | Female (%) | Patients Using Nebulizer Daily at Home as Maintenance Therapy |
|---|---|---|---|---|---|---|---|
| Inhalers + Nebulizers | 47 | 47 | 47 | 47 | 46 | 39 | |
| Oral Medication + Nebulizers + Inhalers | 28 | 26 | 31 | 25 | 32 | 39 | |
| Both in emergency situations and as maintenance/regular use | 53 | 52 | 55 | 56 | 50 | 43 | |
| Solely for maintenance or on a regular basis | 24 | 26 | 22 | 33 | 14 | 54 | |
| >8 weeks (>2 months) | 54 | 60 | 47 | 54 | 54 | 43 | |
| >3–4 weeks (1 month) | 34 | 26 | 43 | 33 | 34 | 43 | |
| In emergency/SOS situations only | 35 | 34 | 35 | 25 | 46 | 0 | |
| Everyday/daily basis | 27 | 28 | 27 | 32 | 22 | 100 | |
| Once a week | 32 | 33 | 31 | 33 | 30 | 0 | |
| Once daily | 55 | 44 | 69 | 44 | 73 | 57 | |
| 2–3 times per day | 45 | 56 | 31 | 56 | 27 | 43 | |
| Yes | 83 | 84 | 82 | 81 | 84 | 86 | |
| No | 17 | 16 | 18 | 19 | 16 | 14 | |
| - | 83 | 78 | 90 | 78 | 88 | 79 | |
| - | 77 | 69 | 86 | 79 | 74 | 86 | |
| DPI | 54 | 48 | 62 | 60 | 49 | ||
| pMDI | 27 | 32 | 20 | 30 | 25 | ||
| - | 70 | 69 | 71 | 64 | 75 | ||
| Once a month | 24 | 18 | 34 | 14 | 33 | ||
| More than once a month | 21 | 27 | 14 | 28 | 16 | ||
| Once in 3 months | 33 | 34 | 31 | 38 | 28 |
Abbreviations: DPI, dry-powder inhaler; QoL, quality of life; pMDI, pressurized metered-dose inhaler; SEC, socio-economic class; SOS, Si Opus Sit (if needed).
Benefits and Concerns with Nebulized Therapy in COPD
| Benefits/Concerns | Overall (%) | SEC A (%) | SEC B (%) | Male (%) | Female (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 89 | 75 | 84 | 74 | 94 | 77 | 88 | 72 | 90 | 78 | |
| 86 | NA | 81 | NA | 92 | NA | 82 | NA | 89 | NA | |
| 85 | 73 | 81 | 67 | 90 | 81 | 86 | 66 | 84 | 79 | |
| 81 | 76 | 72 | 69 | 92 | 86 | 75 | 66 | 88 | 85 | |
| 86 | 70 | 83 | 67 | 90 | 73 | 84 | 65 | 88 | 74 | |
| 84 | 70 | 79 | 67 | 90 | 73 | 82 | 66 | 86 | 73 | |
| 82 | 69 | 79 | 59 | 86 | 83 | 79 | 60 | 86 | 78 | |
| 84 | NA | 83 | NA | 86 | NA | 88 | NA | 80 | NA | |
| 50 | 41 | 57 | 35 | 43 | 49 | 55 | 38 | 46 | 44 | |
| 49 | 43 | 55 | 40 | 43 | 47 | 46 | 48 | 52 | 39 | |
| 48 | 45 | 57 | 39 | 40 | 53 | 44 | 48 | 52 | 42 | |
| NA | 45 | NA | 35 | NA | 58 | NA | 54 | NA | 37 | |
| 45 | 40 | 36 | 31 | 55 | 53 | 46 | 42 | 44 | 39 | |
| 43 | NA | 40 | NA | 47 | NA | 40 | NA | 46 | NA | |
| 41 | 42 | 34 | 37 | 49 | 49 | 42 | 46 | 40 | 39 | |
| 37 | 39 | 29 | 32 | 47 | 49 | 40 | 44 | 34 | 35 | |
| 44 | 40 | 34 | 35 | 55 | 47 | 46 | 48 | 42 | 33 | |
Abbreviations: FCG, family caregiver; NA, not applicable; Pat, patient SEC, socio-economic class.
Figure 1Benefits and concerns with nebulization therapy: a comparison of patients’ and family caregivers’ responses.
Figure 2Comparison of benefits and concerns cited by overall patient population and patients using nebulization daily as home maintenance therapy.
Satisfaction and Compliance with the Nebulizer Therapy
| Parameters | Overall (%) | SEC A (%) | SEC B (%) | Male (%) | Female (%) | |
|---|---|---|---|---|---|---|
| Major role | 69 | 74 | 62 | 68 | 70 | |
| Moderate Role | 28 | 23 | 36 | 30 | 26 | |
| Minor Role | 3 | 3 | 2 | 2 | 4 | |
| Satisfaction rating with level of activities done by family caregivers | 95 | 91 | 100 | 96 | 94 | |
| Patient compliance with the recommended frequency of use of nebulization therapy | 73 | 71 | 76 | 76 | 70 | |
| Rating for family caregiver influence on patient compliance to nebulization therapy | 69 | 67 | 72 | 68 | 71 | |
| The burden of caring for COPD patient negatively impacted the QoL of family caregivers | 60 | 53 | 69 | 62 | 58 | |
| Becoming easily angered | 57 | 56 | 58 | 48 | 64 | |
| Makes me feel sad or worried | 43 | 50 | 36 | 39 | 47 | |
| Low energy levels, often gets tired and exhausted | 41 | 44 | 36 | 42 | 39 | |
| Gain/loss of weight | 35 | 39 | 30 | 33 | 36 | |
| Losing interest in hobbies/social activities | 35 | 31 | 39 | 33 | 36 | |
| Trouble sleeping or sleeping too much | 22 | 28 | 15 | 24 | 19 |
Abbreviations: QoL, quality of life; SEC, socio-economic class.